PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30717909-4	2019	Calcitonin is the specific serum marker; its doubling time is the most important prognostic factor for survival and progression; 30% of MTC patients have distant metastases at diagnosis and, when progressing, systemic therapy with vandetanib or cabozantinib should be considered.	vandetanib	231-241	calcitonin related polypeptide alpha	Homo sapiens	0-10	
30821231-16	2019	Both cabozantinib and vandetanib demonstrated significantly better objective response rates and calcitonin (CTN) and carcinoembryonic antigen (CEA) response rates than placebo.	vandetanib	22-32	calcitonin related polypeptide alpha	Homo sapiens	96-106	
30821231-16	2019	Both cabozantinib and vandetanib demonstrated significantly better objective response rates and calcitonin (CTN) and carcinoembryonic antigen (CEA) response rates than placebo.	vandetanib	22-32	calcitonin related polypeptide alpha	Homo sapiens	108-111	
30821231-19	2019	Within the restricted EU-label population (symptomatic and progressive MTC with CEA/CTN doubling times of <= 24 months), the ICER for vandetanib is expected to be > $66,000 per QALY gained.	vandetanib	137-147	calcitonin related polypeptide alpha	Homo sapiens	84-87